Hyman B. Muss Addresses Misconceptions About Pregnancy and Breast Cancer
Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses misconceptions women have about being pregnant with a breast cancer diagnosis.
Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses misconceptions women have about being pregnant with a breast cancer diagnosis.
While the cancer may initially be more difficult to find since pregnant women’s bodies are going through changes, the treatment and outcomes are about the same when compared to patients with breast cancer who are not pregnant. Muss emphasizes that being pregnant does not mean choosing between treating cancer and having a healthy baby.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
